(Q38008698)

26 August 2017

title

Primary and acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer: an update (English)

1 reference

26 August 2017

1 reference

Ayodele Ayoola

1

1 reference

26 August 2017

Amit Barochia

series ordinal

2

1 reference

26 August 2017

Kiran Belani

series ordinal

3

1 reference

26 August 2017

Chandra P Belani

series ordinal

4

1 reference

26 August 2017

publication date

1 June 2012

1 reference

26 August 2017

1 reference

26 August 2017

volume

30

1 reference

26 August 2017

issue

5

1 reference

26 August 2017

page(s)

433-446

1 reference

26 August 2017

cites work

Cancer statistics, 2012

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2012.666691

Global cancer statistics, 2002

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2012.666691

Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2012.666691

Erlotinib in previously treated non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2012.666691

Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2012.666691

The role of HER2/neu expression and trastuzumab in non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2012.666691

Activation of MET by gene amplification or by splice mutations deleting the juxtamembrane domain in primary resected lung cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2012.666691

Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2012.666691

Somatic mutations affect key pathways in lung adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2012.666691

Epidermal growth factor-related peptides and their receptors in human malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2012.666691

EGF-ERBB signalling: towards the systems level

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2012.666691

ERBB receptors and cancer: the complexity of targeted inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2012.666691

Epidermal growth factor receptor mutations in lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2012.666691

The EGF receptor family as targets for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2012.666691

Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2012.666691

Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2012.666691

Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2012.666691

Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2012.666691

Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 2.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2012.666691

Gefitinib monotherapy in chemotherapy-naive patients with inoperable stage III/IV non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2012.666691

Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2012.666691

Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2012.666691

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2012.666691

Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2012.666691

Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2012.666691

TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2012.666691

Screening for epidermal growth factor receptor mutations in lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2012.666691

Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2012.666691

Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected].

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2012.666691

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2012.666691

Oncogene mutations, copy number gains and mutant allele specific imbalance (MASI) frequently occur together in tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2012.666691

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2012.666691

EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2012.666691

Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2012.666691

Update on epidermal growth factor receptor mutations in non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2012.666691

Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2012.666691

Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2012.666691

Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2012.666691

EGFR mutation and resistance of non-small-cell lung cancer to gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2012.666691

Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2012.666691

MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2012.666691

MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2012.666691

Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2012.666691

Pooled analysis of the prospective trials of gefitinib monotherapy for EGFR-mutant non-small cell lung cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2012.666691

Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2012.666691

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2012.666691

Detection of mutations in EGFR in circulating lung-cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2012.666691

MET increased gene copy number and primary resistance to gefitinib therapy in non-small-cell lung cancer patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2012.666691

Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2012.666691

Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2012.666691

The sensitivity of lung cancer cell lines to the EGFR-selective tyrosine kinase inhibitor ZD1839 ('Iressa') is not related to the expression of EGFR or HER-2 or to K-ras gene status

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2012.666691

KRAS mutation is an important predictor of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2012.666691

Loss of PTEN/MMAC1/TEP in EGF receptor-expressing tumor cells counteracts the antitumor action of EGFR tyrosine kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2012.666691

Phosphorylated Akt overexpression and loss of PTEN expression in non-small cell lung cancer confers poor prognosis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2012.666691

Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2012.666691

The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2012.666691

Acquired resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer: distinct natural history of patients with tumors harboring the T790M mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2012.666691

Structure and clinical relevance of the epidermal growth factor receptor in human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2012.666691

Comparison of the EGFR resistance mutation profiles generated by EGFR-targeted tyrosine kinase inhibitors and the impact of drug combinations

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2012.666691

Hepatocyte growth factor induces gefitinib resistance of lung adenocarcinoma with epidermal growth factor receptor-activating mutations.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2012.666691

ARQ 197, a novel and selective inhibitor of the human c-Met receptor tyrosine kinase with antitumor activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2012.666691

Novel therapeutic inhibitors of the c-Met signaling pathway in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2012.666691

Non-small-cell lung cancer and Ba/F3 transformed cells harboring the ERBB2 G776insV_G/C mutation are sensitive to the dual-specific epidermal growth factor receptor and ERBB2 inhibitor HKI-272.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2012.666691

ErbB-3 mediates phosphoinositide 3-kinase activity in gefitinib-sensitive non-small cell lung cancer cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2012.666691

Baseline gene expression predicts sensitivity to gefitinib in non-small cell lung cancer cell lines.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2012.666691

Epithelial to mesenchymal transition predicts gefitinib resistance in cell lines of head and neck squamous cell carcinoma and non-small cell lung carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2012.666691

Epithelial-mesenchymal transitions in development and pathologies

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2012.666691

Diverse cellular and molecular mechanisms contribute to epithelial plasticity and metastasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2012.666691

Epithelial-mesenchymal transitions in tumour progression

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2012.666691

Epithelial to mesenchymal transition is a determinant of sensitivity of non-small-cell lung carcinoma cell lines and xenografts to epidermal growth factor receptor inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2012.666691

TGF-beta and epithelial-to-mesenchymal transitions

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2012.666691

Requirement of HDAC6 for transforming growth factor-beta1-induced epithelial-mesenchymal transition.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2012.666691

Restoring E-cadherin expression increases sensitivity to epidermal growth factor receptor inhibitors in lung cancer cell lines.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2012.666691

ErbB-3 expression is associated with E-cadherin and their coexpression restores response to gefitinib in non-small-cell lung cancer (NSCLC).

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2012.666691

The TOR pathway: a target for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2012.666691

Overcoming mTOR inhibition-induced paradoxical activation of survival signaling pathways enhances mTOR inhibitors' anticancer efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2012.666691

Rapamycin synergizes with the epidermal growth factor receptor inhibitor erlotinib in non-small-cell lung, pancreatic, colon, and breast tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2012.666691

Pilot randomized phase II study of celecoxib in oral premalignant lesions

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2012.666691

The development of HKI-272 and related compounds for the treatment of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2012.666691

Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2012.666691

BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2012.666691

PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2012.666691

Multicenter, randomized, phase II trial of CI-1033, an irreversible pan-ERBB inhibitor, for previously treated advanced non small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2012.666691

Synchronous overexpression of epidermal growth factor receptor and HER2-neu protein is a predictor of poor outcome in patients with stage I non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2012.666691

10.3109/07357907.2012.666691

21 January 2018

Identifiers

DOI

1 reference

26 August 2017

1 reference